School of Biological Sciences, University of Essex, Colchester, UK.
Chemistry Department, UAE University, Al-Ain, United Arab Emirates.
Biomed J. 2017 Dec;40(6):339-346. doi: 10.1016/j.bj.2017.10.003. Epub 2018 Feb 1.
There is an increasing need to find natural bioactive compounds for pharmaceutical applications, because they have less harmful side effects compared to their chemical alternatives. Microalgae (MA) have been identified as a promising source for these bioactive compounds, and this work aimed to evaluate the anti-proliferative effects of semi-purified protein extracted from MA against several tumor cell lines.
Tested samples comprised MA cell extracts treated with cellulase and lysozyme, prior to extraction. The effect of dialysis, required to remove unnecessary small molecules, was also tested. The anti-cancer efficacies of the dialyzed and undialyzed extracts were determined by measuring cell viability after treating four human cancer cell lines, specifically A549 (human lung carcinoma), MCF-7 (human breast adenocarcinoma), MDA MB-435 (human melanoma), and LNCap (human prostate cancer cells derived from a metastatic site in the lymph node). This was compared to the effects of the agents on the human BPH-1 cell line (benign human prostate epithelial cells). The t-test was used to statistically analyze the results and determine the significance.
Against LNCap and A549 cells, the performance of cellulase-treated extracts was better (with p-values < 0.05, as compared to the control) than that of lysozyme-treated preparations (with p-values mainly > 0.05, as compared to the control); however, they had similar effects against the other two tumor cell lines (with p-values mainly < 0.05, as compared to the control). Moreover, based on their effect on BPH-1 cells, extracts from lysozyme-treated MA cells were determined to be safer against the benign prostate hyperplasia cells, BPH-1 (with p-values mainly > 0.05, as compared to the control). After dialysis, the performance of MA extracts from lysozyme-treated cells was enhanced significantly (with p-values dropping to < 0.05, as compared to the control).
The results of this work provide important information and could provide the foundation for further research to incorporate MA constituents into pharmaceutical anti-cancer therapeutic formulations.
由于与化学替代品相比,天然生物活性化合物的副作用较小,因此人们越来越需要寻找用于药物应用的天然生物活性化合物。微藻 (MA) 已被确定为这些生物活性化合物的有前途的来源,本工作旨在评估从 MA 中提取的半纯化蛋白质对几种肿瘤细胞系的抗增殖作用。
测试样品包括用纤维素酶和溶菌酶处理后的 MA 细胞提取物,然后进行提取。还测试了去除不必要的小分子所需的透析的效果。通过测量四种人癌细胞系(即 A549(人肺癌)、MCF-7(人乳腺癌)、MDA MB-435(人黑色素瘤)和 LNCap(人前列腺癌细胞来源于淋巴结的转移部位))处理后细胞活力来确定透析和未透析提取物的抗癌功效。将这与对人 BPH-1 细胞系(良性人前列腺上皮细胞)的作用进行了比较。使用 t 检验对结果进行统计学分析并确定显著性。
与 LNCap 和 A549 细胞相比,纤维素酶处理的提取物的性能更好(与对照相比,p 值 <0.05),而溶菌酶处理的制剂的性能则较差(与对照相比,p 值主要>0.05);然而,它们对其他两种肿瘤细胞系的作用相似(与对照相比,p 值主要<0.05)。此外,根据它们对 BPH-1 细胞的作用,确定来自溶菌酶处理的 MA 细胞的提取物对良性前列腺增生细胞 BPH-1 更安全(与对照相比,p 值主要>0.05)。透析后,来自溶菌酶处理的 MA 细胞提取物的性能显著增强(与对照相比,p 值降至<0.05)。
本工作的结果提供了重要信息,并为将 MA 成分纳入药物抗癌治疗制剂的进一步研究提供了基础。